- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
SAVE the DATE
The Johns Hopkins University's Institute for NanoBioTechnology (INBT) will be hosting a symposium in Baltimore, Maryland on April 27.
The Johns Hopkins University's Institute for NanoBioTechnology (INBT) will be hosting a symposium in Baltimore, Maryland on April 27. With funding from NIH, NASA and NSF, the Institute was established to revolutionize health care and medicine by bringing together internationally renowned expertise in medicine, engineering, the sciences, and public health to create new knowledge and groundbreaking technologies. The April symposium will focus on: Diagnostics & Therapeutics, Health and the Environment, and Cellular and Molecular Dynamics. Speakers include Piotr Grodzinski (Director, Nanotechnology for Cancer), Dennis Discher, PhD (University of Pennsylvania), David Mooney, PhD (Harvard University), Wendy Sanhai, PhD (FDA), Gregory Downing, PhD (NIH), Michael Sheetz, PhD (Columbia University), and Gang Bao, PhD (Georgia Institute of Technology).
For more information, please click here
Copyright © The Johns Hopkins UniversityIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016
IEDM: Leti CEO Marie Semeria to Give Opening-day Keynote on Impact of ‘Hyperconnectivity’ and IoT: Speech to Portray Key Role Nonprofit Research and Technology Organizations Play in Making Technology More Efficient and Ensuring Safety and Security November 29th, 2016
Cutting-edge nanotechnologies are breaking into industries November 18th, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Making spintronic neurons sing in unison November 18th, 2016